Posted by Michael Wonder on 01 Nov 2023
Empagliflozin for the treatment of adults with chronic heart failure with preserved or mildly reduced ejection fraction
1 November 2023 - NICE has published final evidence-based recommendations on the use of empagliflozin (Jardiance) for the treatment of adults with chronic heart failure with preserved or mildly reduced ejection fraction.
Empagliflozin is recommended as an option for the treatment of adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction.
